Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Aventis Pasteur MSD Adds Chiron's Meng C and Flu Vaccines To Portfolio

  • News

Executive Summary

Aventis Pasteur MSD will sell Chiron's meningococcal C vaccine Menjugate and adjuvanted influenza vaccine Fluad under a co-marketing agreement.

You may also be interested in...



Chiron Acquiring PathoGenesis For Six Times Consensus 2001 Revenues

Chiron will pay about 6.1 times PathoGenesis' consensus 2001 revenues when it acquires the company for approximately $700 mil. cash.

Chiron Acquiring PathoGenesis For Six Times Consensus 2001 Revenues

Chiron will pay about 6.1 times PathoGenesis' consensus 2001 revenues when it acquires the company for approximately $700 mil. cash.

Baxter Acquisition Of NAVA Hinges On Approval of NeisVac-C in U.K.

Baxter's acquisition of North American Vaccine is contingent upon the U.K. approval of NAVA's group C meningococcal conjugate vaccine NeisVac-C.

Table

View full table

Tags:
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS036364

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By